Biocon and Mylan's breast cancer biosimilar receives approval from ANVISA

Photo: Shutterstock
Drug major Biocon and Mylan's proposed biosimilar trastuzumab has been approved by Brazilian regulatory agency ANVISA, through their partner Libbs Farmaceutica (Libbs).

Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.

In a regulatory filing, Biocon said this is the first biosimilar trastuzumab to be approved in Brazil.

Commenting on the development, Biocon CEO and Joint Managing Director Arun Chandavarkar said: "Cancer patients in India and some emerging markets have benefited with our trastuzumab and the approval in Brazil will enable affordable access to this critical biologic therapy for treatment of HER-2 positive breast and gastric cancer in the country".

Biocon said currently biosimilar trastuzumab will be manufactured by it and supplied to Libbs for commercialisation in Brazil.

"Over a period of time the technology will be transferred to Libbs and the public partner Butantan through a product development partnership (PDP).

Earlier this month, the US health regulator approved biosimilar trastuzumab. The proposed biosimilar is also under review by regulatory authorities in Australia, Canada, Europe and several emerging markets.

Shares of Biocon were trading 0.52 per cent lower at Rs 537.40 apiece on BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel